| Identification | Back Directory | [Name]
Gadodiamide | [CAS]
131410-48-5 | [Synonyms]
S-041
Omniscan
GADODIAMIDE
Gd-DTPA-BMA
GADODIAMIDE (500 MG)
gadolinium 2-[bis[2-(carboxylatomethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetate
[5，8-Bis(carboxymethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2，5，8，11-tetraaza-tridecan-13-oato(3-)]gadolinium | [Molecular Formula]
C16H26GdN5O8 | [MDL Number]
MFCD12912458 | [MOL File]
131410-48-5.mol | [Molecular Weight]
573.658 |
| Chemical Properties | Back Directory | [Melting point ]
>300°C (dec.) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Methanol (Slightly, Heated), Water (Slightly) | [form ]
Solid | [color ]
White to Off-White | [CAS DataBase Reference]
131410-48-5 |
| Hazard Information | Back Directory | [Definition]
ChEBI: A non-ionic gadolinium chelate having a macrocyclic triamine framework. It is used as a paramagnetic contrast agent in magnetic resonance imaging (MRI). | [Uses]
efers to the substance containing the water of coordination and multiple (x) waters of hydration. | [General Description]
Gadodiamide is a clear,colorless to slightly yellow, gadolinium-based contrastagent indicated to visualize lesions with abnormal vascularityin the CNS and body. It is a nonionic gadoliniumcomplex administered by intravenous injection with an osmolalityof 2.8 times that of plasma. Gadodiamide decreasesboth the T1 and T2 relaxation times in tissueswhere it is distributed. In clinical MRI, the effect is primarily on the T1 relaxation time resulting in an increase inT1-weighted sequence signal intensity. |
|
|